Xeris Biopharma (XERS) reported $85.81 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 42.8%. EPS of $0.06 for the same period compares to -$0.03 a year ago.
The reported revenue represents a surprise of +5.38% over the Zacks Consensus Estimate of $81.43 million. With the consensus EPS estimate being $0.03, the EPS surprise was +84.62%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Xeris Biopharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product Revenue- Gvoke: $24.65 million compared to the $26.45 million average estimate based on three analysts. The reported number represents a change of +6% year over year. Product Revenue- Recorlev: $45.33 million compared to the $43.67 million average estimate based on three analysts. The reported number represents a change of +307.5% year over year. Revenue- Royalty, contract and other: $2.38 million versus the three-analyst average estimate of $1.02 million. The reported number represents a year-over-year change of -23.3%. Revenue- Product revenue, net: $83.43 million versus the three-analyst average estimate of $81.19 million. The reported number represents a year-over-year change of +46.4%. Product Revenue- Keveyis: $12.8 million versus the three-analyst average estimate of $11.07 million. The reported number represents a year-over-year change of -43.4%.View all Key Company Metrics for Xeris Biopharma here>>>
Shares of Xeris Biopharma have returned -16.9% over the past month versus the Zacks S&P 500 composite's -1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
See Our Newest 5 Stocks Set to Double Picks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Xeris Biopharma Holdings, Inc. (XERS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).